Long-term study shows less frequent and severe pancreatitis following gene therapy for LPLD
Up to 6 years after receiving a single treatment with the gene therapy product lipoprotein lipase (LPL), patients with the debilitating genetic disease LPL deficiency (LPLD) had about 50% fewer episodes of pancreatitis than before receiving the treatment.
Click on this link for more information.
